Intensive Treatment Systems adds Sublocade access across Phoenix-area clinics

Intensive Treatment Systems, a CARF-accredited outpatient medication-assisted treatment provider in Arizona, is highlighting its quality standards and expanded Sublocade care for eligible adults with opioid use disorder. The Phoenix-area provider says the once-monthly buprenorphine injection is now part of treatment options at six clinics and a mobile unit, alongside methadone, Suboxone and other services.

Why it matters: - Intensive Treatment Systems is positioning accredited outpatient care and medication-assisted treatment as a local option for adults seeking opioid use disorder treatment in the Phoenix metro area. - Sublocade may reduce the burden of daily dosing for some eligible patients because it is a once-monthly injectable buprenorphine treatment. - The clinic also says it offers same-day intake, walk-in access and transportation help, which can lower common barriers to starting care.

What happened: - Intensive Treatment Systems said it is highlighting CARF accreditation and access to Sublocade injections for eligible patients. - The provider serves adults across the Phoenix metropolitan area from six clinic locations in Phoenix, Mesa, Glendale and San Tan Valley, plus a mobile treatment unit. - ITS West Clinic operates as a 24/7 walk-in access point. - Same-day intake is available. - Transportation assistance is available. - The organization included the announcement on Aug. 1, 2026.

The details: - CARF accreditation reflects standards tied to quality improvement, person-centered services, program management and measurable outcomes. - ITS says it has maintained CARF-accredited treatment programs for many years. - Treatment offerings include medication-assisted treatment, counseling, psychiatric care, case management and peer recovery support. - Sublocade is an FDA-approved extended-release buprenorphine injection for moderate-to-severe opioid use disorder. - Sublocade may be appropriate for adults who have already started transmucosal buprenorphine or are currently receiving buprenorphine treatment. - A certified healthcare provider administers Sublocade as part of a complete treatment program that includes counseling and psychosocial support. - ITS clinicians assess whether Sublocade, methadone, Suboxone, Vivitrol or another approach fits a patient’s medical needs, history, goals and preferences. - The provider serves members of participating AHCCCS health plans, eligible veterans using TriWest, qualifying people receiving Substance Use Block Grant funding and self-pay patients. - Substance Use Block Grant funding is aimed primarily at uninsured and underinsured people who need treatment and recovery services. - Eligible non-Title 19/21 individuals may qualify for help if they lack AHCCCS coverage, have no other insurance or are underinsured. - Eligibility depends on individual review, program requirements and available funding. - ITS staff can help prospective patients understand enrollment, funding pathways and treatment options. - The provider also offers integrated psychiatric services, certified peer support, aftercare planning and alumni support.

Between the lines: - The announcement blends quality signaling with access messaging, suggesting ITS wants prospective patients and families to view accreditation as part of the treatment decision. - Naming multiple medications and funding paths also signals a broad intake model rather than a one-size-fits-all program. - The emphasis on walk-in and same-day access points to a strategy built around reducing delays between seeking help and starting treatment.

What's next: - Prospective patients are being directed to contact ITS directly for assessment of coverage and funding options. - The clinic will continue matching patients to treatment plans based on clinical evaluation and recovery needs. - Eligible adults can ask whether Sublocade or another medication is the best fit for their care plan.

The bottom line: - ITS is using its CARF accreditation and expanded Sublocade access to reinforce its role as a flexible, outpatient opioid treatment option in the Phoenix area. - More information: the company's announcement